Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration

By /

Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA ® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration.

Scroll to Top